Krystal Biotech (NASDAQ:KRYS) Shares Gap Down to $161.10

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $161.10, but opened at $145.50. Krystal Biotech shares last traded at $156.83, with a volume of 263,735 shares.

Analysts Set New Price Targets

KRYS has been the subject of several analyst reports. Stifel Nicolaus reissued a "buy" rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Krystal Biotech in a report on Monday. William Blair restated an "outperform" rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Finally, Guggenheim lifted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and an average price target of $171.00.

Krystal Biotech Stock Down 2.6 %

The stock has a fifty day moving average price of $169.04 and a two-hundred day moving average price of $133.73. The company has a market cap of $4.47 billion, a price-to-earnings ratio of 1,962.00 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.82. The business had revenue of $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same quarter last year, the firm earned ($1.25) EPS. Analysts predict that Krystal Biotech, Inc. will post 1.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares of the company's stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Insiders have sold 38,087 shares of company stock valued at $6,210,591 in the last ninety days. 14.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC lifted its position in shares of Krystal Biotech by 2.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company's stock valued at $513,000 after acquiring an additional 110 shares during the period. Principal Financial Group Inc. raised its holdings in Krystal Biotech by 2.8% during the first quarter. Principal Financial Group Inc. now owns 5,959 shares of the company's stock worth $1,060,000 after buying an additional 160 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Krystal Biotech by 10.4% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,007 shares of the company's stock worth $349,000 after buying an additional 283 shares during the last quarter. Deutsche Bank AG raised its holdings in Krystal Biotech by 2.8% during the third quarter. Deutsche Bank AG now owns 13,499 shares of the company's stock worth $1,566,000 after buying an additional 365 shares during the last quarter. Finally, EAM Investors LLC raised its holdings in Krystal Biotech by 2.4% during the third quarter. EAM Investors LLC now owns 16,091 shares of the company's stock worth $1,867,000 after buying an additional 377 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).